NCT03185481 - Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 6, 2017

Primary Completion Date

October 24, 2017

Study Completion Date

October 25, 2017

Conditions

Parkinson's Disease With Motor Fluctuations

Interventions

DRUG

1 mg QD to 15 mg QD PF-06649751

Up titration from 1 mg QD to 15 mg QD PF-06649751

DRUG

3 mg QD to 15 mg QD PF-06649751

Up titration from 3 mg QD to 15 mg QD PF-06649751

DRUG

7 mg QD to 15 mg QD PF-06649751

Up titration from 7 mg QD to 15 mg QD PF-06649751

DRUG

15 mg QD PF-06649751

15 mg QD PF-06649751 remaining at 15 mg QD PF-06649751

DRUG

1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)

Up titration from 1 mg QD to 7 mg QD PF-06649751 for subject at 1 mg QD who were blindly de-escalated in the parent study

DRUG

3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)

Up titration from 3 mg QD to 7 mg QD PF-06649751 for 3 mg QD subjects who were blindly de-escalated in parent study

DRUG

7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)

7 mg QD to remain at 7 mg QD PF-06649751 for subjects who were blindly de-escalated in parent study

DRUG

15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD

7mg QD PF-06649751 for subjects assigned to 15 mg QD who were blindly de-escalated to 7 mg QD PF-06649751 in parent study

Trial Locations (9)

30331

Atlanta Center for Medical Research, Atlanta

33486

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton

43614

University of Toledo, Gardner-McMaster Parkinson Center, Toledo

University of Toledo, Investigational Drug Services, Toledo

74136

The Movement Disorder Clinic of Oklahoma, Tulsa

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

98034

Booth Gardner Parkinson's Care Center, Kirkland

06824

Associated Neurologists of Southern CT, PC, Fairfield

08053

Pharmaceutical Research Associates, Inc., Marlton